诱导多能干细胞来源NK细胞疗法在胶质母细胞瘤中诱导持久缓解并通过B7-H3靶向三特异性杀伤衔接器克服耐药
该临床前研究评估了诱导多能干细胞来源的NK产品FT538在胶质母细胞瘤模型中的疗效。FT538对77%的胶质母细胞瘤干细胞样细胞系具有杀伤活性,颅内给药耐受良好且持续至少35天,单次瘤内注射使敏感移植瘤完全消退;B7-H3靶向三特异性杀伤衔接器可恢复耐药肿瘤对NK细胞的敏感性。
要点
- FT538对77%的胶质母细胞瘤干细胞样细胞系具有杀伤活性。
- 颅内给药耐受良好,持续至少35天,无神经毒性。
- B7-H3靶向TriKE可克服耐药,增强抗肿瘤疗效。
核心结论
- FT538在77%的胶质母细胞瘤干细胞样细胞系中表现出强效杀肿瘤活性,在敏感模型中具有治愈潜力,并在体内表现出良好的持续性和耐受性。
- B7-H3靶向TriKE可恢复耐药肿瘤的NK敏感性。
- 这些发现为FT538单用或联合B7-H3靶向TriKE用于胶质母细胞瘤及其他实体瘤的进一步临床评估提供了强有力的临床前依据。
研究设计与样本
- 临床前研究:在13例患者来源的胶质母细胞瘤干细胞样细胞(GSC)体外实验及原位异种移植模型中测试FT538。
- FT538为临床级诱导多能干细胞来源的NK产品,经工程化改造含高亲和力不可切割CD16 Fc受体、膜结合IL-15/IL-15Rα融合蛋白及CD38敲除。
- 在小鼠中评估颅内持续性和神经毒性;通过表面蛋白质组学鉴定治疗靶点,并评估B7-H3靶向三特异性杀伤衔接器(TriKE)与FT538及NKG2C+适应性NK细胞的联合效果。
主要发现
- 胶质母细胞瘤干细胞样细胞对FT538的敏感性分类为:敏感(38%)、中度敏感(38%)、耐药(23%)。
- 小鼠颅内给药耐受良好,持续至少35天,未引起神经毒性。
- 单次瘤内剂量在敏感异种移植瘤中诱导完全消退。
- 表面谱分析确定B7-H3为克服耐药的靶点。
- FT538联合B7-H3 TriKE在耐药模型中增强抗肿瘤疗效,适应性NK细胞也观察到该效果。
临床怎么用
- FT538单用或联合B7-H3靶向TriKE可能成为胶质母细胞瘤及其他实体瘤的潜在免疫治疗策略,需进一步临床评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Glioblastoma is the most aggressive primary brain tumor, with a poor prognosis and limited treatment options. Natural killer (NK) cell therapy is a promising immunotherapeutic strategy; yet, its efficacy remains limited. We evaluated FT538, a clinical-grade NK product derived from induced pluripotent stem cells (iPSCs), in glioblastoma models. METHODS: FT538, engineered with a high-affinity noncleavable CD16 Fc receptor, a membrane-bound IL-15/IL-15Rα fusion protein, and CD38 knockout, was tested against 13 patient-derived glioblastoma stem-like cells (GSCs) in vitro and in orthotopic xenograft models. Intracranial persistence and neurotoxicity were assessed in mice. Surface proteomics identified therapeutic targets, and a B7-H3-targeted tri-specific killer engager (TriKE) was evaluated with FT538 and NKG2C+ adaptive NK cells. RESULTS: Glioblastoma stem-like cells were classified as sensitive (38%), moderately sensitive (38%), or resistant (23%) to FT538. Intracranial administration in mice was well tolerated, persisted for at least 35 days, and caused no neurotoxicity. A single intratumoral dose induced complete regression in sensitive xenografts. Surface profiling identified B7-H3 as a target to overcome resistance. Combination therapy with FT538 and a B7-H3 TriKE enhanced antitumor efficacy in resistant models, an effect also observed with adaptive NK cells. CONCLUSIONS: FT538 exhibits potent tumoricidal activity in 77% of GSC lines (NK-sensitive and moderately sensitive), with curative potential in sensitive models, and demonstrates favorable persistence and tolerability in vivo. B7-H3-targeted TriKE restores NK sensitivity in resistant tumors. These findings provide a strong preclinical rationale for further clinical evaluation of FT538, alone or combined with B7-H3-targeted TriKE, for glioblastoma and other solid tumors. Glioblastoma is a type of aggressive brain tumor with a dismal survival rate. Due to the limited effectiveness of current treatments, new therapies are critically needed. In this study, we combined 2 novel therapeutics: (1) a genetically modified immune cell called a natural killer (NK) cell and (2) a tumor antigen targeting engager that works together to target NK cells to kill glioblastoma cells. When used together to treat mice with patient derived glioblastoma tumors, the combination of these 2 therapies significantly enhanced the survival. These results provide strong evidence supporting this strategy for the treatment of glioblastoma.
引用
- Ning JF, Davis ZB, Zeb Q, et al. Induced pluripotent stem cell-derived natural killer cell therapy induces durable responses in glioblastoma and overcomes resistance via a B7-H3-targeted tri-specific killer engager. Neuro Oncol. 2026. PMID: 42434963. doi:10.1093/neuonc/noag154
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。